Provided herein are methods of detecting an analyte of interest to interrogate spatial gene expression in a sample using RNA-templated ligation.

Provided herein are methods of detecting an analyte of interest to interrogate spatial gene expression in a sample using RNA-templated ligation.

A fluid analyzer for analyzing fluid samples comprising one or more analytes and a method of calibrating such. The fluid analyzer includes a control system to control at least one automated valve to pass at least three calibration reagents through a fluid channel to a secondary ion selective electrode, a primary ion selective electrode, and a reference electrode, and determine calibration information using calibration logic from signals generated by a meter, control the at least one automated valve to selectively pass different subsets of the at least three calibration reagents through the fluid channel to the secondary ion selective electrode, the primary ion selective electrode, and the reference electrode, and determine re-calibration information using the signals generated by the meter and at least one of the calibration information and re-calibration logic.

A fluid analyzer for analyzing fluid samples comprising one or more analytes and a method of calibrating such. The fluid analyzer includes a control system to control at least one automated valve to pass at least three calibration reagents through a fluid channel to a secondary ion selective electrode, a primary ion selective electrode, and a reference electrode, and determine calibration information using calibration logic from signals generated by a meter, control the at least one automated valve to selectively pass different subsets of the at least three calibration reagents through the fluid channel to the secondary ion selective electrode, the primary ion selective electrode, and the reference electrode, and determine re-calibration information using the signals generated by the meter and at least one of the calibration information and re-calibration logic.

A polypeptide having epoxy group-removing catalytic activity with an amino acid sequence as set forth in SEQ ID NOs: 1-35, a nucleic acid molecule encoding the polypeptide, a nucleic acid construct comprising the nucleic acid, a pharmaceutical composition for detoxification and a food, beverage or feed composition comprising the polypeptide, and a host cell and an engineered microorganism into which the nucleic acid is introduced. Disclosed are a method for producing the polypeptide; and a method for catalyzing a reaction of removing an epoxy group of a trichothecene, a method for preventing cell poisoning or relieving cytotoxicity, a method for processing a food and beverage or feed composition, and a method for reducing or decreasing a toxin in a composition, all using the polypeptide. Further disclosed are a glutathionylated derivative, a method for evaluating the detoxification effect for a sample contaminated with a trichothecene using the glutathionylated derivative.

A polypeptide having epoxy group-removing catalytic activity with an amino acid sequence as set forth in SEQ ID NOs: 1-35, a nucleic acid molecule encoding the polypeptide, a nucleic acid construct comprising the nucleic acid, a pharmaceutical composition for detoxification and a food, beverage or feed composition comprising the polypeptide, and a host cell and an engineered microorganism into which the nucleic acid is introduced. Disclosed are a method for producing the polypeptide; and a method for catalyzing a reaction of removing an epoxy group of a trichothecene, a method for preventing cell poisoning or relieving cytotoxicity, a method for processing a food and beverage or feed composition, and a method for reducing or decreasing a toxin in a composition, all using the polypeptide. Further disclosed are a glutathionylated derivative, a method for evaluating the detoxification effect for a sample contaminated with a trichothecene using the glutathionylated derivative.

A diagnostic assay for detecting an occurrence of a stroke event in a mammalian subject. The assay comprises the steps of: (i) separating a plasma fraction from a blood sample collected from the mammalian subject; (ii) quantifying in the plasma fraction a L-glutamine hydroxylamine glutamyl transferase (L-GHGT) activity; (iii) quantifying in the plasma fraction a gamma glutamyl hydroxamate synthetase (GGHS) activity; (iv) adding together or alternatively calculating the combinatorial probability for the quantified L-GHGT activity and the quantified GGHS activity to produce a value for the net glutamine synthetase activity, and (v) correlating the net glutamine synthetase activity value with net glutamine synthetase activity values from healthy subjects to detect an occurrence of a stroke event in the mammalian subject. Also disclosed are kits comprising reagents and instructions for performing a diagnostic assay to detect and quantify L-GHGT activity and/or GGHS activity.

A diagnostic assay for detecting an occurrence of a stroke event in a mammalian subject. The assay comprises the steps of: (i) separating a plasma fraction from a blood sample collected from the mammalian subject; (ii) quantifying in the plasma fraction a L-glutamine hydroxylamine glutamyl transferase (L-GHGT) activity; (iii) quantifying in the plasma fraction a gamma glutamyl hydroxamate synthetase (GGHS) activity; (iv) adding together or alternatively calculating the combinatorial probability for the quantified L-GHGT activity and the quantified GGHS activity to produce a value for the net glutamine synthetase activity, and (v) correlating the net glutamine synthetase activity value with net glutamine synthetase activity values from healthy subjects to detect an occurrence of a stroke event in the mammalian subject. Also disclosed are kits comprising reagents and instructions for performing a diagnostic assay to detect and quantify L-GHGT activity and/or GGHS activity.

A method for producing alpha-glucosidase inhibitors utilizing Paenibacillus sp., wherein utilizing a Paenibacillus sp. strain which is deposited at Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ) and numbered No. DSM 32521 to produce the alpha-glucosidase inhibitors, the Paenibacillus sp. Strain is cultivated in a commercial culture medium or a shrimp/crab residue-contained culture medium, and the alpha-glucosidase inhibitors is separated from a fermented supernatant. The alpha-glucosidase inhibitors have strong inhibitory activity.

A method for producing alpha-glucosidase inhibitors utilizing Paenibacillus sp., wherein utilizing a Paenibacillus sp. strain which is deposited at Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH (DSMZ) and numbered No. DSM 32521 to produce the alpha-glucosidase inhibitors, the Paenibacillus sp. Strain is cultivated in a commercial culture medium or a shrimp/crab residue-contained culture medium, and the alpha-glucosidase inhibitors is separated from a fermented supernatant. The alpha-glucosidase inhibitors have strong inhibitory activity.